These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 22793066

  • 1. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T.
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [Abstract] [Full Text] [Related]

  • 2. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT.
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH, Kim JH, Yu H, Shin E, Cho H, Kim H, Yang WS, Han DJ, Park SK.
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [Abstract] [Full Text] [Related]

  • 4. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
    Gavela Martínez E, Avila Bernabeu AI, Sancho Calabuig A, Beltrán Catalán S, Escudero Quesada V, Pallardó Mateu LM.
    Transplant Proc; 2009 Jan; 41(6):2337-8. PubMed ID: 19715913
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [Abstract] [Full Text] [Related]

  • 9. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Mar; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 10. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S, Vasta F, Mandalà L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B.
    Transplant Proc; 2005 Mar; 37(6):2611-3. PubMed ID: 16182762
    [Abstract] [Full Text] [Related]

  • 11. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T, Yoshimura N, Ushigome H, Watarai Y, Nishimura K, Akioka K, Nakamura N, Kawakita M, Yuzawa K, Nakatani T.
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [Abstract] [Full Text] [Related]

  • 12. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 13. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP.
    Lancet; 1997 Oct 25; 350(9086):1193-8. PubMed ID: 9652559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb 20; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

  • 18. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S.
    Saudi J Kidney Dis Transpl; 2014 Jan 20; 25(1):9-15. PubMed ID: 24434376
    [Abstract] [Full Text] [Related]

  • 19. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 20; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 20. Initial data on basiliximab in critically ill children undergoing heart transplantation.
    Ford KA, Cale CM, Rees PG, Elliott MJ, Burch M.
    J Heart Lung Transplant; 2005 Sep 20; 24(9):1284-8. PubMed ID: 16143246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.